🧠 Prazosin for PTSD Nightmares Simulator

Untreated PTSD Sleep — Noradrenergic Storm in REM

Trauma memory replay is fueled by excess noradrenergic tone during REM sleep.

• 6–7: Nightmare nights/wk (typical untreated PTSD)
• High: REM noradrenaline (excess locus coeruleus tone)
• Poor: Sleep continuity (frequent awakenings)
• Elevated: Daytime hyperarousal (carries into waking hours)

Why nightmares recur

Overactive locus coeruleus floods REM sleep with norepinephrine, replaying trauma.

Hyperarousal cycle

Poor sleep worsens daytime arousal, reinforcing the nightly nightmare cycle.

Starting Prazosin — Low Dose, Bedtime, Gradual Increase

Treatment begins low and rises slowly to limit first-dose blood pressure drops.

• 1 mg: Starting dose (bedtime, first-dose caution)
• weekly: Titration step (gradual upward adjustment)
• 1–20 mg: Target range (individualized ceiling)
• Watch: First-dose effect (orthostatic drop risk)

Slow, cautious ramp

Dose rises gradually across days to weeks, monitoring tolerability closely.

First-dose caution

Initial doses carry the highest orthostatic hypotension risk.

Blocking Alpha-1 Receptors During Sleep

Prazosin blocks alpha-1 receptors, muting noradrenergic signaling overnight.

• Alpha-1 blocker: Mechanism (selective antagonist)
• CNS + vascular: Site of action (brain and periphery)
• Days: Onset of effect (dose-dependent ramp)
• ~70–90%: Blockade at target dose (estimated occupancy)

Receptor occupancy

Higher doses occupy more alpha-1 receptors, further muting REM signaling.

Selective action

Blockade targets noradrenergic overdrive without sedating the brain broadly.

Nightmare Frequency Falls With Effective Blockade

As titration reaches an effective dose, nightmare nights become far less frequent.

• 1–2: Nightmare nights/wk (at effective dose)
• 2–4 wks: Response window (to reach effect)
• Marked: Symptom relief (frequency and intensity both drop)
• Improved: Sleep quality (fewer awakenings)

Dose-response benefit

Nightmare frequency falls steadily as blockade rises toward target.

Calendar view

Weekly nightmare nights thin out visibly across the titration timeline.

Balancing Nightmare Relief Against Orthostatic Risk

Higher doses help sleep more but raise orthostatic hypotension risk modestly.

• Improved: Sleep outcome (less distress, better continuity)
• Dose-dependent: Hypotension risk (rises modestly with dose)
• BP checks: Monitoring (especially after dose increases)
• Favorable: Net benefit (when titrated carefully)

Finding the balance

The effective dose maximizes nightmare relief while limiting hypotension risk.

Ongoing care

Careful titration and monitoring sustain benefit long term.